Shares of Alder BioPharmaceuticals Inc. (NASDAQ:ALDR) fell 0.5% on Friday . The stock traded as low as $26.07 and last traded at $26.45, with a volume of 170,307 shares trading hands. The stock had previously closed at $26.58.

Several brokerages have recently weighed in on ALDR. Zacks Investment Research downgraded shares of Alder BioPharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, May 3rd. Brean Capital reaffirmed a “buy” rating on shares of Alder BioPharmaceuticals in a report on Saturday, April 30th. Wells Fargo & Co. began coverage on shares of Alder BioPharmaceuticals in a report on Thursday, April 21st. They issued an “outperform” rating on the stock. Leerink Swann reaffirmed an “outperform” rating on shares of Alder BioPharmaceuticals in a report on Tuesday, March 29th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of Alder BioPharmaceuticals in a report on Thursday, June 30th. One research analyst has rated the stock with a hold rating and five have given a buy rating to the stock. Alder BioPharmaceuticals presently has an average rating of “Buy” and an average price target of $52.00.

The company has a 50 day moving average price of $27.66 and a 200-day moving average price of $25.66. The company’s market cap is $1.35 billion.

Alder BioPharmaceuticals (NASDAQ:ALDR) last posted its quarterly earnings data on Thursday, April 28th. The biopharmaceutical company reported ($0.76) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.72) by $0.04. During the same quarter in the previous year, the company posted ($0.40) EPS. On average, analysts forecast that Alder BioPharmaceuticals Inc. will post ($3.25) EPS for the current year.

In other Alder BioPharmaceuticals news, VP Jeffrey T. L. Smith sold 16,090 shares of the stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $30.20, for a total transaction of $485,918.00. Following the sale, the vice president now directly owns 16,090 shares of the company’s stock, valued at $485,918. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Mark James Litton sold 25,000 shares of the stock in a transaction on Tuesday, May 31st. The stock was sold at an average price of $30.05, for a total transaction of $751,250.00. Following the sale, the insider now directly owns 79,847 shares in the company, valued at $2,399,402.35. The disclosure for this sale can be found here.

Several hedge funds have modified their holdings of the company. Nationwide Fund Advisors boosted its stake in shares of Alder BioPharmaceuticals by 103.6% in the fourth quarter. Nationwide Fund Advisors now owns 30,380 shares of the biopharmaceutical company’s stock worth $1,003,000 after buying an additional 15,457 shares during the period. ProShare Advisors LLC boosted its stake in shares of Alder BioPharmaceuticals by 8.6% in the fourth quarter. ProShare Advisors LLC now owns 38,476 shares of the biopharmaceutical company’s stock worth $1,271,000 after buying an additional 3,058 shares during the period. Pyrrho Capital Management LP boosted its stake in shares of Alder BioPharmaceuticals by 205.0% in the fourth quarter. Pyrrho Capital Management LP now owns 63,000 shares of the biopharmaceutical company’s stock worth $2,081,000 after buying an additional 42,343 shares during the period. California Public Employees Retirement System boosted its stake in shares of Alder BioPharmaceuticals by 834.5% in the fourth quarter. California Public Employees Retirement System now owns 81,300 shares of the biopharmaceutical company’s stock worth $2,685,000 after buying an additional 72,600 shares during the period. Finally, Wells Fargo & Company MN boosted its stake in shares of Alder BioPharmaceuticals by 290.6% in the fourth quarter. Wells Fargo & Company MN now owns 269,774 shares of the biopharmaceutical company’s stock worth $8,911,000 after buying an additional 200,707 shares during the period.

Alder Biopharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.